Quest Diagnostics Incorporated vs Samsung Electronics Co., Ltd.: Strategic Comparison

This in-depth comparison examines Quest Diagnostics Incorporated and Samsung Electronics Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Quest Diagnostics Incorporated on its own, evaluating Samsung Electronics Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Quest Diagnostics Incorporated and Samsung Electronics Co., Ltd. is widest.

On the headline numbers, Quest Diagnostics Incorporated reports annual revenue of $11.0B against ~$236.9B for Samsung Electronics Co., Ltd., while their respective market capitalizations stand at $27.2B and $1.33T. Quest Diagnostics Incorporated is headquartered in United States and Samsung Electronics Co., Ltd. in South Korea, and those different home markets shape how each company competes.

Quest Diagnostics Incorporated: Quest Diagnostics is a Secaucus, New Jersey-based provider of diagnostic information services. It does not make drugs or run hospitals. It runs the labs that process blood, urine and tissue samples ordered by doctors, hospitals, employers and consumers, then sends results back through EHRs and the MyQuest app. Quest says it serves about one in three adult Americans and half the physicians and hospitals in the U.S. each year. Since 2024 it has also run LifeLabs in Canada.

Samsung Electronics Co., Ltd.: Samsung Electronics, based in Suwon, is the flagship company of the Samsung Group and South Korea's most valuable listed company. It is the world's largest memory chipmaker and one of the two largest smartphone vendors. Its market value passed $1 trillion in May 2026 and was about $1.33 trillion in late September 2026, after its shares more than tripled in a year on AI memory demand. The company is led by co-CEOs Jun Young-hyun (semiconductors) and TM Roh (devices), with Jay Y. Lee as Executive Chairman.

Quest Diagnostics Incorporated and Samsung Electronics Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Quest Diagnostics Incorporated and Samsung Electronics Co., Ltd..

Quest Diagnostics Incorporated business model: Quest Diagnostics earns fee-for-service revenue for lab tests ordered by physicians, hospitals, health plans, employers and consumers. Diagnostic Information Services (DIS) produced $2.978B of the company's $3.043B Q2 2026 revenue. Payment comes from commercial insurers, Medicare and Medicaid, hospitals that send it outreach or reference work, employers, and patients paying directly through questhealth.com. Volume drives the economics. Specimens collected at about 2,200 patient service centers and physician offices are moved by courier, and on some routes by air, to regional labs. High-throughput automated testing there keeps the cost per test low. Routine tests such as metabolic panels, lipid panels and blood counts make up most of the volume. Advanced diagnostics like AD-Detect Alzheimer's blood tests, Haystack MRD, genetics and cardiometabolic panels carry higher prices. Hospital outreach acquisitions and Co-Lab lab-management deals add volume.

Samsung Electronics Co., Ltd. business model: Samsung earns money from two groups of businesses. Device Solutions (DS) makes and sells memory (DRAM, HBM, NAND), System LSI chips such as Exynos processors and ISOCELL image sensors, and contract foundry manufacturing. In Q2 2026, DS produced ~$90.5 billion (KRW 127.5 trillion) of the company's ~$122 billion (KRW 171.5 trillion) revenue and ~$63.3 billion (KRW 89.2 trillion) of its ~$63.5 billion (KRW 89.5 trillion) operating profit. Device eXperience (DX) sells Galaxy phones, tablets, wearables, TVs, monitors and home appliances, plus network equipment. Separately consolidated subsidiaries add OLED panels from Samsung Display, sold to Apple and other phone makers, and automotive and audio electronics from Harman.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Quest Diagnostics Incorporated stack up against those of Samsung Electronics Co., Ltd..

Quest Diagnostics Incorporated competitive advantage: Quest's main advantage is density. It has a national patient service center footprint, in-network contracts with most major U.S. health plans, EHR connections to physician offices, and regional labs that spread fixed costs across hundreds of millions of tests a year. Only Labcorp operates at comparable U.S. scale. That scale lets Quest offer health systems a lower-cost option for outreach testing. Deals with NewYork-Presbyterian, Corewell Health and Fresenius Medical Care show how it turns that into new volume.

Samsung Electronics Co., Ltd. competitive advantage: Samsung's edge is manufacturing scale and breadth. It is the largest memory producer and one of only three major DRAM makers, alongside SK hynix and Micron. That lets it capture pricing upswings like the 2026 AI-driven shortage. It also owns component businesses (memory, OLED through Samsung Display, image sensors) that sell to rivals as well as to its own Galaxy devices, so it earns money even when competitors' products win.

Future prospects matter as much as current results. The growth strategies below explain how Quest Diagnostics Incorporated and Samsung Electronics Co., Ltd. each plan to expand from here.

Quest Diagnostics Incorporated growth strategy: Quest is growing in four ways. First, it buys hospital outreach labs and signs Co-Lab Solutions lab-management deals, such as its Corewell Health joint venture in Michigan. Second, it adds large partner volume, such as dialysis testing for Fresenius Medical Care. Third, it pushes higher-value advanced diagnostics, including AD-Detect Alzheimer's blood tests, Haystack MRD (approved by New York State in 2026) and liver fibrosis testing. Fourth, it sells consumer-initiated tests through questhealth.com and wearable and wellness partners. Automation and AI in specimen processing, cervical cancer screening and the IntelliDraw collection tool are meant to offset reimbursement pressure.

Samsung Electronics Co., Ltd. growth strategy: Samsung's growth plan centers on AI memory: ramping HBM4 for Nvidia and AMD accelerators, developing HBM4E, and adding DRAM capacity at Pyeongtaek. In foundry it is pursuing 2nm gate-all-around production and building its Taylor, Texas fab to win customers from TSMC. On the device side it relies on Galaxy AI features, foldables and premium TVs to defend share against Apple and Chinese brands.

A closer look at the financial trajectory of Quest Diagnostics Incorporated and Samsung Electronics Co., Ltd. rounds out the comparison.

Quest Diagnostics Incorporated: Quest's results follow three phases. Before the pandemic, revenue grew slowly, from $7.21B in 2016 to $7.73B in 2019. COVID-19 testing then lifted revenue to $10.79B and net income to $1.995B in 2021. Revenue fell back to $9.25B in 2023 as that demand faded. Acquisitions and organic volume restarted growth: revenue reached $9.87B in 2024 and $11.035B in 2025, when operating income was $1.556B and operating cash flow was $1.886B. In the first half of 2026, revenue rose 9.7% to $5.938B and net income attributable to Quest rose 13.9% to $572M. Quest raised its quarterly dividend 7.5% to $0.86 per share in 2026.

Samsung Electronics Co., Ltd.: Samsung's earnings follow the memory cycle. Revenue fell from ~$215 billion (KRW 302.2 trillion) in 2022 to ~$184 billion (KRW 258.9 trillion) in 2023 during a chip downturn, then recovered to ~$214 billion (KRW 300.9 trillion) in 2024 and ~$237 billion (KRW 333.6 trillion) in 2025, when net income reached about $31.5 billion (KRW 44.3 trillion). In 2026, AI server demand created a memory shortage. Q1 operating profit of ~$40.6 billion (KRW 57.2 trillion) exceeded the full-year 2025 total, and Q2 reached ~$63.5 billion (KRW 89.5 trillion) on ~$122 billion (KRW 171.5 trillion) revenue. Higher memory costs also squeezed Samsung's own devices: the MX and Networks unit lost ~$497 million (KRW 0.7 trillion) in Q2 2026 on ~$23.6 billion (KRW 33.2 trillion) revenue.